作者: Sreeman K Mamidyala , Steven M Firestine
DOI: 10.1517/13543776.16.11.1463
关键词:
摘要: Herpes simplex viruses (HSV) are responsible for usually non-life threatening infections of the oral, ocular and genital regions. The infect a significant percentage US population almost two million new cases reported each year. Present medicinal agents that treat HSV target catalytic activity virally encoded DNA polymerase. Although these have been shown to be safe efficacious, many possess limited oral bioavailability, must given early in disease process maximum effect resistance is problem immunocompromised individuals. Thus, there need continued development anti-HSV agents. This review discusses published medical patent literature during 2004 – 2006 highlights recent advances nucleoside non-nucleoside inhibitors polymerase, helicase–primase complex, viral entry compounds no ...